Form 4 for KNSA Kiniksa Pharmaceuticals International, plc
Accepted 2025-04-23 00:00:00 ET · period of report 2025-04-21 · accession 0001415889-25-011209 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-23 | 2025-04-21 | KNSA | Moat Ross | Chief COMMERCIAL Off | S - Sale | $20.29 | -18.3K | 9,415 | -66% | -$370.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Ordinary Share | 2025-04-21 | S | D | 18,259 | $20.29 | 9,415 | D | — | — | (F2) This transaction was executed in multiple trades through a broker-dealer at prices ranging between $20.05 and 20.53. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price. |